-+ 0.00%
-+ 0.00%
-+ 0.00%

Turn Therapeutics Q1 FY26 net loss widens to $970,972; G&A expenses rise to $1.14 million

PUBT·05/11/2026 20:07:17
Listen to the news
Turn Therapeutics Q1 FY26 net loss widens to $970,972; G&A expenses rise to $1.14 million
  • Turn Therapeutics posted a net loss of USD 970,972, or USD 0.03 per share, for three months ended March 31, 2026, versus a net loss of USD 328,547, or USD 0.01 per share, a year earlier.
  • Operating loss widened to USD 1.25 million as total operating expenses climbed to USD 1.25 million; G&A rose to USD 1.14 million.
  • Cash and cash equivalents increased to USD 11.2 million at March 31, 2026, following funding of an initial USD 7 million tranche under a growth capital facility providing access to up to USD 25 million in term loans.
  • Phase 2 trial of GX-03 in moderate-to-severe atopic dermatitis remained on track, with interim results expected in Q2 2026 and topline data expected mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Turn Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605111605BIZWIRE_USPR_____20260511_BW828716) on May 11, 2026, and is solely responsible for the information contained therein.